Stanley Capital completed the acquisition of Noden Pharmaceutical Business from PDL BioPharma for $53m.

Stanley Capital, a private equity partnership, completed the acquisition of Noden Pharma DAC and Noden Pharma USA, a global speciality pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas, from PDL BioPharma, which acquires, manages and commercializes commercial-stage pharmaceutical assets and late clinical-stage pharmaceutical products, for $53m. "After running an extensive process, we are excited about closing this transaction with Stanley Capital. It represents the completion of a key divestiture for PDL and an exciting opportunity for the Noden team," Dominique Monnet, PDL's President and CEO.